Trials / Conditions / Mesotheliomas Pleural

Mesotheliomas Pleural

17 registered clinical trials studyying Mesotheliomas Pleural — 8 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Partial Pleurectomy (Surgery) for Unresectable Pleural Mesothelioma NCT07126509	University of Chicago	N/A
Recruiting	A Study of Sacituzumab Govitecan in People With Mesothelioma NCT06477419	Memorial Sloan Kettering Cancer Center	Phase 2
Recruiting	Ga-68 FAPI PET Before Immunotherapy NCT06451536	Ankara University	N/A
Recruiting	Immune Microenvironment and Gene Expression Profiling in Mesothelioma NCT06581549	Istituto Oncologico Veneto IRCCS	—
Recruiting	Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MP NCT03760575	Abramson Cancer Center at Penn Medicine	Phase 1
Terminated	Oral AMXT 1501 Dicaprate in Combination With IV DFMO NCT05500508	Aminex Therapeutics, Inc.	Phase 1 / Phase 2
Active Not Recruiting	A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer NCT05451849	TCR2 Therapeutics	Phase 1 / Phase 2
Recruiting	The IMmunotherapy Pleural 5-ALA PDT NCT04400539	University Hospital, Lille	Phase 2
Unknown	Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including NCT05278975	RS Oncology LLC	Phase 1 / Phase 2
Recruiting	Atezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso) NCT04996017	Gruppo Oncologico Italiano di Ricerca Clinica	Phase 3
Recruiting	dENdritic Cell Therapy Combined With SURgEry in Mesothelioma NCT05304208	Erasmus Medical Center	Phase 1
Active Not Recruiting	Pembrolizumab Plus Lenvatinib In Second Line and Third Line Malignant Pleural mesotheLioma Patients NCT04287829	The Netherlands Cancer Institute	Phase 2
Active Not Recruiting	Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma NCT04300244	Åslaug Helland	Phase 2
Withdrawn	A Pilot Study to Explore the Role of Gut Flora in Metastatic Mesothelioma NCT04214015	ProgenaBiome	—
Active Not Recruiting	Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer NCT03907852	TCR2 Therapeutics	Phase 1 / Phase 2
Unknown	A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors NCT03475953	Institut Bergonié	Phase 1 / Phase 2
Completed	CAR T Cells in Mesothelin Expressing Cancers NCT03054298	University of Pennsylvania	Phase 1